Creating organoids from advanced or recurrent ovarian cancer for drug testing
Drug Response in Patient-derived Organoids Models of Advanced or Recurrent Ovarian Cancer, an Exploratory Research
This study is trying to create mini versions of ovarian cancer tumors from patients with advanced or recurrent cancer to see how well different drugs work on them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Chongqing University Cancer Hospital Academic / other |
| Locations | 1 site (Chongqing, Chongqing) |
| Trial ID | NCT05290961 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with advanced or recurrent ovarian cancer whose tumors cannot be completely excised. It aims to establish organoids from these tumors to evaluate their histopathological and genetic characteristics, ensuring they accurately represent the original tumor. The study will assess the sensitivity and specificity of various drugs using these organoids, comparing the results with actual clinical outcomes to develop a precise drug screening platform. This approach seeks to innovate drug research and development tailored to individual patient needs.
Who should consider this trial
Good fit: Ideal candidates are patients with advanced or recurrent ovarian cancer who are scheduled for surgery but cannot have their tumors fully removed.
Not a fit: Patients with active serious infections, severe liver disease, or other significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized treatment options for patients with advanced or recurrent ovarian cancer.
How similar studies have performed: While the use of organoids for drug screening is a growing field, this specific approach in ovarian cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients voluntarily participated in the study and signed informed consent; 2. The tumour cannot be excised thoroughly by surgery; 3. ECOG score ≤ 2; 4. Expected survival \>6 months; 5. Blood routine test: Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L; 6. Both serum ALT and serum AST ≤ 2 × ULN； blood creatinine ≤ 1.5 × ULN; 7. Unpregnant women (negative HCG) received contraception in the study; 8. Good compliance is judged by researchers. Exclusion Criteria: 1. Active or the uncontrol serious infections; 2. Patients with liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis need antiviral treatment; 3. A history of immune deficiency, including HIV positive or other acquired congenital immune deficiency diseases; 4. Chronic renal insufficiency and renal failure; 5. Myocardial infarction, severe arrhythmia and congestive heart failure (≥ grade 2 according to NYHA classification); 6. Autoimmune diseases, including systemic lupus erythematosus; 7. Patients take drugs that damage liver and kidney function for other complications, such as tuberculosis; 8. Patients cannot understand the experimental contents and refuse to sign the informed consent form; 9. Other concomitant serious diseases harm the health of patients or interfere with the study.
Where this trial is running
Chongqing, Chongqing
- Chongqing University Cancer Hospital — Chongqing, Chongqing, China (Recruiting)
Study contacts
- Principal investigator: Dongling Zou, M.D. — Chongqing University Cancer Hospital
- Study coordinator: Dongling Zou, M.D.
- Email: cqzl_zdl@163.com
- Phone: 13657690699
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.